A “skinny label” is one way that a generic drug can be commercialized in the US when only a subset of the brand’s uses lose exclusivity. The recent Supreme Court decision in the Caraco case may put a spotlight on the opportunities for “skinny label” generics. The article found here describes some of the issues and possible policy implications that may be associated with an increased use of “skinny labels.”
Identifying and optimizing the Medical Affairs talent pool
Insights from the MAPS New Orleans 2025 roundtable session. The session highlighted the essential talent needs—such as competencies, qualifications, and...